{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:46:07Z","timestamp":1788371167327,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40120-023-00573-7","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T12:02:12Z","timestamp":1704456132000},"page":"21-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Insights for Healthcare Providers on Shared Decision-Making in Multiple Sclerosis: A Narrative Review"],"prefix":"10.1007","volume":"13","author":[{"given":"Sharon","family":"Stoll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Newsome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy B.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Hendin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"573_CR1","unstructured":"World Medical Association. WMA Declaration of Geneva. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-geneva\/. Accessed 16 Sep 2022."},{"key":"573_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1352458516671204","volume":"23","author":"E Colligan","year":"2017","unstructured":"Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis. Mult Scler. 2017;23:185\u201390.","journal-title":"Mult Scler"},{"key":"573_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1007\/s00415-021-10836-8","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Danesi R, Derfuss T, et al. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2022;269:1670\u20137.","journal-title":"J Neurol"},{"key":"573_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/cer-2020-0267","volume":"10","author":"IA Samjoo","year":"2021","unstructured":"Samjoo IA, Worthington E, Drudge C, et al. Efficacy classification of modern therapies in multiple sclerosis. J Comp Eff Res. 2021;10:495\u2013507.","journal-title":"J Comp Eff Res"},{"key":"573_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","volume":"15","author":"N Scolding","year":"2015","unstructured":"Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15:273\u20139.","journal-title":"Pract Neurol"},{"key":"573_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/PPA.S115090","volume":"11","author":"M Tintore","year":"2017","unstructured":"Tintore M, Alexander M, Costello K, et al. The state of multiple sclerosis: current insight into the patient\/health care provider relationship, treatment challenges, and satisfaction. Patient Prefer Adherence. 2017;11:33\u201345.","journal-title":"Patient Prefer Adherence"},{"key":"573_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.7224\/1537-2073.2017-070","volume":"20","author":"A Ben-Zacharia","year":"2018","unstructured":"Ben-Zacharia A, Adamson M, Boyd A, et al. Impact of shared decision making on disease-modifying drug adherence in multiple sclerosis. Int J MS Care. 2018;20:287\u201397.","journal-title":"Int J MS Care"},{"key":"573_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777\u201388.","journal-title":"Neurology"},{"key":"573_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40120-018-0118-8","volume":"7","author":"D Yeandle","year":"2018","unstructured":"Yeandle D, Rieckmann P, Giovannoni G, Alexandri N, Langdon D. Patient power revolution in multiple sclerosis: navigating the new frontier. Neurol Ther. 2018;7:179\u201387.","journal-title":"Neurol Ther"},{"key":"573_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.7224\/1537-2073.2016-091","volume":"19","author":"SS Cofield","year":"2017","unstructured":"Cofield SS, Thomas N, Tyry T, Fox RJ, Salter A. Shared decision making and autonomy among US participants with multiple sclerosis in the NARCOMS Registry. Int J MS Care. 2017;19:303\u201312.","journal-title":"Int J MS Care"},{"key":"573_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103751","volume":"61","author":"RN Alonso","year":"2022","unstructured":"Alonso RN, Chertcoff A, Eizaguirre MB, et al. Decision making process in multiple sclerosis: an Argentine pilot study. Mult Scler Relat Disord. 2022;61:103751.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR12","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","volume":"389","author":"G Comi","year":"2017","unstructured":"Comi G, Radaelli M, Soelberg SP. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017;389:1347\u201356.","journal-title":"Lancet"},{"key":"573_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.693017","volume":"12","author":"CS Simonsen","year":"2021","unstructured":"Simonsen CS, Flemmen HO, Broch L, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2\u00a0years in a Norwegian population-based registry. Front Neurol. 2021;12:693017.","journal-title":"Front Neurol"},{"key":"573_CR14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19:307\u201316.","journal-title":"Lancet Neurol"},{"key":"573_CR15","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","volume":"76","author":"K Harding","year":"2019","unstructured":"Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536\u201341.","journal-title":"JAMA Neurol"},{"key":"573_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.autrev.2017.04.010","volume":"16","author":"B Merkel","year":"2017","unstructured":"Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev. 2017;16:658\u201365.","journal-title":"Autoimmun Rev"},{"key":"573_CR17","unstructured":"Biogen Inc. TYSABRI prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125104s973s975lbl.pdf. Accessed 12 Oct 2022."},{"key":"573_CR18","unstructured":"Merck. MAVENCLAD prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022561s006lbl.pdf. Accessed 12 Oct 2022."},{"key":"573_CR19","unstructured":"Genentech Inc. OCREVUS prescribing information. https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf. Accessed 12 Oct 2022."},{"key":"573_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102507","volume":"46","author":"A Manzano","year":"2020","unstructured":"Manzano A, Eskyte I, Ford HL, et al. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020;46:102507.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/1756285616631897","volume":"9","author":"PK Coyle","year":"2016","unstructured":"Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord. 2016;9:198\u2013210.","journal-title":"Ther Adv Neurol Disord"},{"key":"573_CR22","first-page":"1","volume":"12","author":"R Villaverde-Gonzalez","year":"2022","unstructured":"Villaverde-Gonzalez R. Updated perspectives on the challenges of managing multiple sclerosis during pregnancy. Degener Neurol Neuromuscul Dis. 2022;12:1\u201321.","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"573_CR23","doi-asserted-by":"crossref","unstructured":"Kew KM, Malik P, Aniruddhan K, Normansell R. Shared decision-making for people with asthma. Cochrane Database Syst Rev. 2017;10:CD012330.","DOI":"10.1002\/14651858.CD012330.pub2"},{"key":"573_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ypmed.2016.09.034","volume":"93","author":"EB Peterson","year":"2016","unstructured":"Peterson EB, Ostroff JS, DuHamel KN, et al. Impact of provider-patient communication on cancer screening adherence: a systematic review. Prev Med. 2016;93:96\u2013105.","journal-title":"Prev Med"},{"key":"573_CR25","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.pec.2017.06.030","volume":"100","author":"M Saheb Kashaf","year":"2017","unstructured":"Saheb Kashaf M, McGill ET, Berger ZD. Shared decision-making and outcomes in type\u00a02 diabetes: a systematic review and meta-analysis. Patient Educ Couns. 2017;100:2159\u201371.","journal-title":"Patient Educ Couns"},{"key":"573_CR26","doi-asserted-by":"crossref","first-page":"238146831880850","DOI":"10.1177\/2381468318808503","volume":"3","author":"ASL Tan","year":"2018","unstructured":"Tan ASL, Mazor KM, McDonald D, et al. Designing shared decision-making interventions for dissemination and sustainment: can implementation science help translate shared decision making into routine practice? MDM Policy Pract. 2018;3:2381468318808503.","journal-title":"MDM Policy Pract"},{"key":"573_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13012-016-0480-9","volume":"11","author":"G Elwyn","year":"2016","unstructured":"Elwyn G, Frosch DL, Kobrin S. Implementing shared decision-making: consider all the consequences. Implement Sci. 2016;11:114.","journal-title":"Implement Sci"},{"key":"573_CR28","unstructured":"Consortium of Multiple Sclerosis Centers. NARCOMMS Registry for multiple sclerosis. https:\/\/www.narcoms.org\/. Accessed 28 Oct 2022."},{"key":"573_CR29","unstructured":"COViMS. COVID-19 Infections in MS and Related Diseases. https:\/\/www.covims.org\/. Accessed 22 Nov 2022."},{"key":"573_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001104","volume":"9","author":"FBS Briggs","year":"2022","unstructured":"Briggs FBS, Mateen FJ, Schmidt H, et al. COVID-19 vaccination reactogenicity in persons with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1104.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"573_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102512","volume":"46","author":"AC Vogel","year":"2020","unstructured":"Vogel AC, Schmidt H, Loud S, McBurney R, Mateen FJ. Impact of the COVID-19 pandemic on the health care of >1,000 people living with multiple sclerosis: a cross-sectional study. Mult Scler Relat Disord. 2020;46:102512.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR32","unstructured":"NAAMS Registry. National African Americans with MS Registry. https:\/\/www.naamsr.org\/. Accessed 22 Nov 2022."},{"key":"573_CR33","first-page":"205521731772510","volume":"3","author":"L Amezcua","year":"2017","unstructured":"Amezcua L, Oksenberg JR, McCauley JL. MS in self-identified Hispanic\/Latino individuals living in the US. Mult Scler J Exp Transl Clin. 2017;3:2055217317725103.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"573_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12911-020-01211-0","volume":"20","author":"LA Shinkunas","year":"2020","unstructured":"Shinkunas LA, Klipowicz CJ, Carlisle EM. Shared decision making in surgery: a scoping review of patient and surgeon preferences. BMC Med Inform Decis Mak. 2020;20:190.","journal-title":"BMC Med Inform Decis Mak"},{"key":"573_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152041","volume":"56","author":"T Morrison","year":"2022","unstructured":"Morrison T, Foster E, Dougherty J, Barton J. Shared decision making in rheumatology: a scoping review. Semin Arthritis Rheum. 2022;56:152041.","journal-title":"Semin Arthritis Rheum"},{"key":"573_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1472-6947-14-81","volume":"14","author":"KD Wyatt","year":"2014","unstructured":"Wyatt KD, Branda ME, Inselman JW, et al. Genders of patients and clinicians and their effect on shared decision making: a participant-level meta-analysis. BMC Med Inform Decis Mak. 2014;14:81.","journal-title":"BMC Med Inform Decis Mak"},{"key":"573_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240371","volume":"15","author":"EL Adisso","year":"2020","unstructured":"Adisso EL, Zomahoun HTV, Gogovor A, Legare F. Sex and gender considerations in implementation interventions to promote shared decision making: a secondary analysis of a Cochrane systematic review. PLoS ONE. 2020;15:e0240371.","journal-title":"PLoS ONE"},{"key":"573_CR38","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.2105\/AJPH.2013.301631","volume":"103","author":"EL Mead","year":"2013","unstructured":"Mead EL, Doorenbos AZ, Javid SH, et al. Shared decision-making for cancer care among racial and ethnic minorities: a systematic review. Am J Public Health. 2013;103:e15-29.","journal-title":"Am J Public Health"},{"key":"573_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.amjsurg.2018.01.011","volume":"216","author":"TM Hughes","year":"2018","unstructured":"Hughes TM, Merath K, Chen Q, et al. Association of shared decision-making on patient-reported health outcomes and healthcare utilization. Am J Surg. 2018;216:7\u201312.","journal-title":"Am J Surg"},{"key":"573_CR40","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3899\/jrheum.131350","volume":"41","author":"JL Barton","year":"2014","unstructured":"Barton JL, Trupin L, Tonner C, et al. English language proficiency, health literacy, and trust in physician are associated with shared decision making in rheumatoid arthritis. J Rheumatol. 2014;41:1290\u20137.","journal-title":"J Rheumatol"},{"key":"573_CR41","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/art.21988","volume":"55","author":"JP Berrios-Rivera","year":"2006","unstructured":"Berrios-Rivera JP, Street RL Jr, Garcia Popa-Lisseanu MG, et al. Trust in physicians and elements of the medical interaction in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum. 2006;55:385\u201393.","journal-title":"Arthritis Rheum"},{"key":"573_CR42","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/art.11467","volume":"49","author":"MM Ward","year":"2003","unstructured":"Ward MM, Sundaramurthy S, Lotstein D, Bush TM, Neuwelt CM, Street RL Jr. Participatory patient-physician communication and morbidity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;49:810\u20138.","journal-title":"Arthritis Rheum"},{"key":"573_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104465","volume":"70","author":"R Alonso","year":"2022","unstructured":"Alonso R, Carnero Contentti E, Grana M, et al. Shared decision making in the treatment of multiple sclerosis: a consensus based on Delphi methodology. Mult Scler Relat Disord. 2022;70:104465.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060721","volume":"8","author":"E Pietrolongo","year":"2013","unstructured":"Pietrolongo E, Giordano A, Kleinefeld M, et al. Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments. PLoS ONE. 2013;8:e60721.","journal-title":"PLoS ONE"},{"key":"573_CR45","doi-asserted-by":"publisher","first-page":"204062232311729","DOI":"10.1177\/20406223231172920","volume":"14","author":"AB Ben-Zacharia","year":"2023","unstructured":"Ben-Zacharia AB, Lee JM, Kahle JS, Lord B. Shared decision-making in multiple sclerosis physical symptomatic care: a systematic review. Ther Adv Chronic Dis. 2023;14:20406223231172920.","journal-title":"Ther Adv Chronic Dis"},{"key":"573_CR46","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1080\/09638288.2017.1283448","volume":"40","author":"E Held Bradford","year":"2018","unstructured":"Held Bradford E, Finlayson M, White Gorman A, Wagner J. Maximizing gait and balance: behaviors and decision-making processes of persons with multiple sclerosis and physical therapists. Disabil Rehabil. 2018;40:1014\u201325.","journal-title":"Disabil Rehabil"},{"key":"573_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fneur.2017.00065","volume":"8","author":"G Saposnik","year":"2017","unstructured":"Saposnik G, Sempere AP, Prefasi D, et al. Decision-making in multiple sclerosis: the role of aversion to ambiguity for therapeutic inertia among neurologists (DIScUTIR MS). Front Neurol. 2017;8:65.","journal-title":"Front Neurol"},{"key":"573_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/hex.12599","volume":"21","author":"IEH Kremer","year":"2018","unstructured":"Kremer IEH, Evers S, Jongen PJ, Hiligsmann M. Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: a best-worst scaling. Health Expect. 2018;21:171\u201380.","journal-title":"Health Expect"},{"key":"573_CR49","doi-asserted-by":"crossref","unstructured":"Members of the MS in the 21st Century Steering Group, Rieckmann P, Centonze D, et al. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: a combined perspective from the MS in the 21st Century Steering Group. Mult Scler Relat Disord. 2018;19:153\u2013160.","DOI":"10.1016\/j.msard.2017.11.013"},{"key":"573_CR50","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/ane.12881","volume":"137","author":"C Heesen","year":"2018","unstructured":"Heesen C, Haase R, Melzig S, et al. Perceptions on the value of bodily functions in multiple sclerosis. Acta Neurol Scand. 2018;137:356\u201362.","journal-title":"Acta Neurol Scand"},{"key":"573_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101929","volume":"39","author":"LA Visser","year":"2020","unstructured":"Visser LA, Louapre C, Uyl-de Groot CA, Redekop WK. Patient needs and preferences in relapsing-remitting multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2020;39:101929.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR52","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2147\/PPA.S306498","volume":"15","author":"J Kumar","year":"2021","unstructured":"Kumar J, Cambron-Mellott MJ, Tencer T, Will O, Mackie DS, Beusterien K. Patient and neurologist preferences in the United States for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment. Patient Prefer Adherence. 2021;15:1515\u201327.","journal-title":"Patient Prefer Adherence"},{"key":"573_CR53","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jns.2016.12.038","volume":"375","author":"GK Reen","year":"2017","unstructured":"Reen GK, Silber E, Langdon DW. Multiple sclerosis patients\u2019 understanding and preferences for risks and benefits of disease-modifying drugs: a systematic review. J Neurol Sci. 2017;375:107\u201322.","journal-title":"J Neurol Sci"},{"key":"573_CR54","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7224\/1537-2073.2017-043","volume":"20","author":"V Schlegel","year":"2018","unstructured":"Schlegel V, Leray E. From medical prescription to patient compliance: a qualitative insight into the neurologist-patient relationship in multiple sclerosis. Int J MS Care. 2018;20:279\u201386.","journal-title":"Int J MS Care"},{"key":"573_CR55","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.pedn.2021.09.008","volume":"61","author":"LV Duffy","year":"2021","unstructured":"Duffy LV, Sarill K, Forbes P, Camposano S, McCabe M. Shared decision making and disease modifying therapy in families of children and adolescents with pediatric onset multiple sclerosis. J Pediatr Nurs. 2021;61:404\u20139.","journal-title":"J Pediatr Nurs"},{"key":"573_CR56","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","volume":"11","author":"MP Wattjes","year":"2015","unstructured":"Wattjes MP, Rovira A, Miller D, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis\u2014establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015;11:597\u2013606.","journal-title":"Nat Rev Neurol"},{"key":"573_CR57","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/ane.13082","volume":"139","author":"K Engels","year":"2019","unstructured":"Engels K, Schiffmann I, Weierstall R, et al. Emotions towards magnetic resonance imaging in people with multiple sclerosis. Acta Neurol Scand. 2019;139:497\u2013504.","journal-title":"Acta Neurol Scand"},{"key":"573_CR58","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","volume":"15","author":"D Rotstein","year":"2019","unstructured":"Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15:287\u2013300.","journal-title":"Nat Rev Neurol"},{"key":"573_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103404","volume":"58","author":"G Saposnik","year":"2022","unstructured":"Saposnik G, Andhavarapu S, Fernandez O, et al. Factors associated with treatment escalation among MS specialists and general neurologists: results from an international cojoint study. Mult Scler Relat Disord. 2022;58:103404.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.856240","volume":"13","author":"M Freund","year":"2022","unstructured":"Freund M, Schiffmann I, Rahn AC, et al. Understanding Magnetic Resonance Imaging in Multiple Sclerosis (UMIMS): development and piloting of an online education program about magnetic resonance imaging for people with multiple sclerosis. Front Neurol. 2022;13:856240.","journal-title":"Front Neurol"},{"key":"573_CR61","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.socscimed.2018.01.015","volume":"208","author":"MH Cadden","year":"2018","unstructured":"Cadden MH, Arnett PA, Tyry TM, Cook JE. Judgment hurts: the psychological consequences of experiencing stigma in multiple sclerosis. Soc Sci Med. 2018;208:158\u201364.","journal-title":"Soc Sci Med"},{"key":"573_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102261","volume":"44","author":"M Hanna","year":"2020","unstructured":"Hanna M, Strober LB. Anxiety and depression in multiple sclerosis (MS): antecedents, consequences, and differential impact on well-being and quality of life. Mult Scler Relat Disord. 2020;44:102261.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR63","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/1359105314522085","volume":"21","author":"MC Goodworth","year":"2016","unstructured":"Goodworth MC, Stepleman L, Hibbard J, et al. Variables associated with patient activation in persons with multiple sclerosis. J Health Psychol. 2016;21:82\u201392.","journal-title":"J Health Psychol"},{"key":"573_CR64","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/13548506.2016.1274043","volume":"22","author":"MF Possa","year":"2017","unstructured":"Possa MF, Minacapelli E, Canale S, Comi G, Martinelli V, Falautano M. The first year after diagnosis: psychological impact on people with multiple sclerosis. Psychol Health Med. 2017;22:1063\u201371.","journal-title":"Psychol Health Med"},{"key":"573_CR65","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1212\/WNL.0000000000002887","volume":"87","author":"G Wang","year":"2016","unstructured":"Wang G, Marrie RA, Salter AR, et al. Health insurance affects the use of disease-modifying therapy in multiple sclerosis. Neurology. 2016;87:365\u201374.","journal-title":"Neurology"},{"key":"573_CR66","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.msard.2019.07.005","volume":"35","author":"N Frost","year":"2019","unstructured":"Frost N, Freeman J, Brixner D, Mort J, Clem J, Ngorsuraches S. Patients\u2019 preferences and willingness-to-pay for disease-modifying therapies. Mult Scler Relat Disord. 2019;35:55\u201360.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102720","volume":"48","author":"N Poudel","year":"2021","unstructured":"Poudel N, Banjara B, Kamau S, Frost N, Ngorsuraches S. Factors influencing patients\u2019 willingness-to-pay for disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2021;48:102720.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR68","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7224\/1537-2073.2020-026","volume":"23","author":"CD Mayo","year":"2021","unstructured":"Mayo CD, Farzam-Kia N, Ghahari S. Identifying barriers to and facilitators of health service access encountered by individuals with multiple sclerosis. Int J MS Care. 2021;23:37\u201344.","journal-title":"Int J MS Care"},{"key":"573_CR69","first-page":"179","volume":"295","author":"H Kuusisto","year":"2022","unstructured":"Kuusisto H, Apila S, Saranto K. Information provision and quality. A pilot study on shared decision-making in multiple sclerosis. Stud Health Technol Inform. 2022;295:179\u201382.","journal-title":"Stud Health Technol Inform"},{"key":"573_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101467","volume":"37","author":"F De Kleermaeker","year":"2020","unstructured":"De Kleermaeker F, Uitdehaag BMJ, van Oosten BW. Patients\u2019 expectations of autologous hematopoietic stem cell transplantation as a treatment for MS. Mult Scler Relat Disord. 2020;37:101467.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103259","volume":"56","author":"CR Wicks","year":"2021","unstructured":"Wicks CR, Sloan R, DiMauro S, et al. Patients\u2019 experiences of self-identification, seeking support, and anticipation of potential relapse in multiple sclerosis. Mult Scler Relat Disord. 2021;56:103259.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40120-021-00299-4","volume":"11","author":"J Kesselring","year":"2022","unstructured":"Kesselring J, Boyko A, Laroni A, Bharadia T, van Galen P, Alexandri N. Caregiver involvement in MS: duty or disruption? Neurol Ther. 2022;11:9\u201320.","journal-title":"Neurol Ther"},{"key":"573_CR73","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jval.2017.12.015","volume":"21","author":"GK Reen","year":"2018","unstructured":"Reen GK, Silber E, Langdon DW. Best methods of communicating clinical trial data to improve understanding of treatments for patients with multiple sclerosis. Value Health. 2018;21:762\u20136.","journal-title":"Value Health"},{"key":"573_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101433","volume":"37","author":"JA Hoffmann","year":"2020","unstructured":"Hoffmann JA, Bareuther L, Schmidt R, Dettmers C. The relation between memory and decision-making in multiple sclerosis patients. Mult Scler Relat Disord. 2020;37:101433.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR75","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1037\/hea0000626","volume":"37","author":"JM Bruce","year":"2018","unstructured":"Bruce JM, Jarmolowicz DP, Lynch S, et al. How patients with multiple sclerosis weigh treatment risks and benefits. Health Psychol. 2018;37:680\u201390.","journal-title":"Health Psychol"},{"key":"573_CR76","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s13063-020-04855-5","volume":"21","author":"I Schiffmann","year":"2020","unstructured":"Schiffmann I, Freund M, Vettorazzi E, et al. Assessing the effect of an evidence-based patient online educational tool for people with multiple sclerosis called UMIMS\u2014understanding magnetic resonance imaging in multiple sclerosis: study protocol for a double-blind, randomized controlled trial. Trials. 2020;21:1008.","journal-title":"Trials"},{"key":"573_CR77","doi-asserted-by":"publisher","first-page":"v","DOI":"10.7224\/1537-2073.2018-098","volume":"20","author":"C Heesen","year":"2018","unstructured":"Heesen C, Rahn AC. Guest Editorial: shared decision making in managing multiple sclerosis: revisiting the research agenda. Int J MS Care. 2018;20:v\u2013vi.","journal-title":"Int J MS Care"},{"key":"573_CR78","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14737175.2016.1217155","volume":"17","author":"E Cocco","year":"2017","unstructured":"Cocco E, Caoci A, Lorefice L, Marrosu MG. Perception of risk and shared decision making process in multiple sclerosis. Expert Rev Neurother. 2017;17:173\u201380.","journal-title":"Expert Rev Neurother"},{"key":"573_CR79","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMp1508418","volume":"373","author":"L Rosenbaum","year":"2015","unstructured":"Rosenbaum L. The paternalism preference\u2014choosing unshared decision making. N Engl J Med. 2015;373:589\u201392.","journal-title":"N Engl J Med"},{"key":"573_CR80","doi-asserted-by":"crossref","unstructured":"K\u00f6pke S, Solari A, Khan F, Heesen C, Giordano A. Information provision for people with multiple sclerosis. Cochrane Database Syst Rev. 2014:CD008757.","DOI":"10.1002\/14651858.CD008757.pub2"},{"key":"573_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103728","volume":"60","author":"A Schneider","year":"2022","unstructured":"Schneider A, Fasshauer E, Scheiderbauer J, et al. Development and evaluation of evidence-based patient information handbooks about multiple sclerosis immunotherapies. Mult Scler Relat Disord. 2022;60:103728.","journal-title":"Mult Scler Relat Disord"},{"key":"573_CR82","first-page":"205521732110299","volume":"7","author":"N Bansback","year":"2021","unstructured":"Bansback N, Chiu JA, Metcalfe R, et al. Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis. Mult Scler J Exp Transl Clin. 2021;7:20552173211029970.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"573_CR83","first-page":"CD001431","volume":"4","author":"D Stacey","year":"2017","unstructured":"Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431.","journal-title":"Cochrane Database Syst Rev"},{"key":"573_CR84","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/jama.2017.10289","volume":"318","author":"D Stacey","year":"2017","unstructured":"Stacey D, Legare F, Lewis KB. Patient decision aids to engage adults in treatment or screening decisions. JAMA. 2017;318:657\u20138.","journal-title":"JAMA"},{"key":"573_CR85","doi-asserted-by":"crossref","first-page":"238146831987913","DOI":"10.1177\/2381468319879134","volume":"4","author":"N Col","year":"2019","unstructured":"Col N, Alvarez E, Springmann V, et al. A novel tool to improve shared decision making and adherence in multiple sclerosis: development and preliminary testing. MDM Policy Pract. 2019;4:2381468319879134.","journal-title":"MDM Policy Pract"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00573-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00573-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00573-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T15:10:01Z","timestamp":1705158601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00573-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00573-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"assertion":[{"value":"6 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sharon Stoll has served on scientific advisory boards for Bristol Myers Squibb, F. Hoffmann-La Roche Ltd., Genentech, Forepont Capital Partners, Horizon, and TG Therapeutics; received research support from BeCare MS Link and MedDay Pharmaceuticals; received compensation for consulting services, served on scientific advisory boards, and received speaker honoraria for Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Horizon, Novartis, Roche\/Genentech, and Sanofi\/Genzyme; is CEO of Global Consultant MD; and serves on the steering committee of Horizon and Roche\/Genentech. Kathleen Costello has served on advisory boards for Bristol Myers Squibb, Genentech, Novartis, and Sanofi. Can Do MS has received support from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Novartis, Sanofi, Sandoz, TG Therapeutics, and Viatris. Scott D. Newsome\u00a0reports consultant fees for scientific advisory boards from Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Greenwich Biosciences, Horizon Therapeutics, Novartis, and TG Therapeutics; is an adviser for Autobahn; is the study lead principal investigator for a Roche clinical trial; was a clinical trial adjudication committee member for MedDay Pharmaceuticals; and has received research funding (paid directly to institution) from Biogen, Genentech, National Multiple Sclerosis Society (NMSS), Patient-Centered Outcomes Research Institute (PCORI), Roche, Stiff Person Syndrome Research Foundation, and US Department of Defense. Hollie Schmidt works for the Accelerated Cure Project for MS (ACP), which has received grants, collaboration funding, payments for use of assets, or in-kind contributions from the following companies: AbbVie, AstraZeneca, BC Platforms, Biogen, Bristol Myers Squibb, Celgene, EMD Serono, Genentech, GlycoMinds, Mallinckrodt, MedDay Pharmaceuticals, MSDx, Novartis, Octave, Pfizer, Regeneron Genetics Center, Sandoz, Sanofi\/Genzyme, and Teva. ACP has also received funding from PCORI and NMSS. Amy B. Sullivan has served as a consultant and speaker for Biogen, Bristol Myers Squibb, EMD Serono, Genentech, and Novartis. Barry Hendin has received research, advisory, or speaker\u2019s bureau support from Alexion, Biogen, EMD Serono, Genentech, Genzyme, Horizon, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}